Our work provides a distinct and complementary contribution by addressing a broader set of five specific clinical aims, including tumor grading, molecular subtyping (e.g., IDH status), and distinguishing glioma from other entities Like PCNSL. The gene discussed is IDH1; the disease is neoplasm.